Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Cardinal Health 200, LLC

US Class I Ongoing · initiated 2026-03-02

Non-Sterility: microbial contamination identified as Paenibacillus phoenicis

New Life Pharma LLC

US Class II Ongoing · initiated 2026-02-26

Lack of Assurance of Sterility

New Life Pharma LLC

US Class II Ongoing · initiated 2026-02-26

Lack of Assurance of Sterility

New Life Pharma LLC

US Class II Ongoing · initiated 2026-02-26

Lack of Assurance of Sterility

New Life Pharma LLC

US Class II Ongoing · initiated 2026-02-26

Lack of Assurance of Sterility

MACLEODS PHARMA USA, INC

US Class II Ongoing · initiated 2026-02-26

Subpotent Drug

Champignons et Adaptogènes

Canada Type III Ongoing · initiated 2026-02-26

Dosage. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.Conta…

MYLAN PHARMACEUTICALS INC

US Class II Ongoing · initiated 2026-02-24

Failed Dissolution Specifications

Radnostix

US Class III Ongoing · initiated 2026-02-19

Failed Tablet/Capsule Specifications

Cipla USA, Inc.

US Class III Ongoing · initiated 2026-02-18

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection te…

HTO Nevada Inc. dba Kirkman

US Class II Ongoing · initiated 2026-02-18

Stability Data Does Not Support Expiry Date.

HTO Nevada Inc. dba Kirkman

US Class II Ongoing · initiated 2026-02-18

Stability Data Does Not Support Expiry Date.

HTO Nevada Inc. dba Kirkman

US Class II Ongoing · initiated 2026-02-18

Stability Data Does Not Support Expiry Date.

Cipla USA, Inc.

US Class III Ongoing · initiated 2026-02-18

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection te…

CEFAZOLIN FOR INJECTION USP 10 G / VIAL

Canada Type I Ongoing · initiated 2026-02-18

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

Teva-Indomethacin

Canada Type II Ongoing · initiated 2026-02-18

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

The Harvard Drug Group LLC

US Class II Ongoing · initiated 2026-02-17

Defective container; inadequately sealed blister packaging.

APO-CANDESARTAN

Canada Type II Ongoing · initiated 2026-02-16

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

AvKARE

US Class II Ongoing · initiated 2026-02-13

Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.

Harbin Jixianglong Biotech Co., Ltd.

US Class II Ongoing · initiated 2026-02-13

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Harbin Jixianglong Biotech Co., Ltd.

US Class II Ongoing · initiated 2026-02-13

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Seasonique and Seasonale Tablets

Canada Type I Ongoing · initiated 2026-02-13

Product quality. Do not skip any doses or stop taking Seasonique or Seasonale.If your package is missing a blister card or any pills, return it to your pharmacy…

Slate Run Pharmaceuticals

US Class III Ongoing · initiated 2026-02-12

Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved s…

LEO PHARMA INC

US Class II Ongoing · initiated 2026-02-10

Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.

Meitheal Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-02-09

Defective Delivery System: Missing or duplicated needles within the injection kit